ORAMED PHARMACEUTICALS INC.

For the period ended Jun 30, 2026. Filed Aug 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 10, 2026

ORMP$3.97-0.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Comprehensive Income

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

Six months ended · Three months ended
June 30, · June 30, · June 30, · June 30,
2026 · 2025 · 2026 · 2025
REVENUES	$	-	2,000	$	-	-
COST OF REVENUE		-	(1,987)		-	-
GROSS PROFIT		-	13		-	-
RESEARCH AND DEVELOPMENT EXPENSES		(1,594)	(3,240)		-	(1,034)
GENERAL AND ADMINISTRATIVE EXPENSES		(4,831)	(3,762)		(2,766)	(1,455)
OPERATING LOSS		(6,425)	(6,989)		(2,766)	(2,489)
OTHER INCOME, NET		8,860	257		610	257
FINANCIAL INCOME, NET		148,592	12,808		103,743	15,366
INCOME BEFORE TAX EXPENSES		$151,027	6,076		$101,587	13,134
TAX BENEFIT (EXPENSES)		(34,561)	(458)		(23,431)	126
NET INCOME		$116,466	5,618		$78,156	13,260
NET INCOME (LOSS) ATTRIBUTABLE TO:
NON-CONTROLLING INTERESTS		-	(28)		-	(28)
COMPANY’S STOCKHOLDERS		116,466	5,646		78,156	13,288
BASIC INCOME PER SHARE OF COMMON STOCK		$2.85	$0.14		$1.90	$0.32
DILUTED INCOME PER SHARE OF COMMON STOCK		$2.76	$0.13		$1.84	$0.31
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC INCOME PER SHARE OF COMMON STOCK		40,907,909	41,488,994		41,040,479	41,743,486
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING DILUTED INCOME PER SHARE OF COMMON STOCK		42,236,456	42,884,004		42,501,252	42,609,425

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.